Organon's Implanon Contraceptive Gets Second "Approvable" Letter
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA requests more information from Organon on its implantable contraceptive Implanon following receipt of a second "approvable" letter. The company also awaits FTC clearance of a marketing and distribution agreement with Merck KGaA subsidiary Laboratoire Théramex for an oral contraceptive.
You may also be interested in...
Organon’s Implanon Is First Single-Rod Implantable Contraceptive
The etonogestrel implant will be available in conjunction with launch of Organon’s physician training program by the end of August.
Organon’s Implanon Is First Single-Rod Implantable Contraceptive
The etonogestrel implant will be available in conjunction with launch of Organon’s physician training program by the end of August.
Organon Abandons Gepirone Following Second “Not Approvable” Letter
Company will withdraw NDA for the antidepressant, which it had planned to market as Variza. With Implanon, Organon has one potential 2004 launch remaining; other new products are not expected before 2006-2007